期刊文献+

丙米嗪合并阿立派唑治疗难治性抑郁症的临床观察 被引量:1

A clinical study on aripiprazde combined with imipramine in treatment-refractory depression
下载PDF
导出
摘要 目的:观察丙米嗪合并阿立派唑治疗难治性抑郁症的疗效和不良反应。方法:采用入院顺序分层随机法,将82例难治性抑郁症患者分为研究组(阿立派唑+丙米嗪)和对照组(丙米嗪+安慰剂),在治疗前、治疗后4、8w末分别用汉密尔顿抑郁量表(HAMD)、总体疗效量表(CG I)和副反应量表(TESS)评定疗效和不良反应。结果:治疗4 w后研究组HAMD总分及各因子分比治疗前明显降低,且治疗组因子分显著低于对照组;治疗后TESS评分,4 w末研究组高于对照组,8 w末两组无显著性差异。结论:丙米嗪合并阿立派唑治疗难治性抑郁症有一定的疗效。 Objective: To observe the efficacy and side effects of aripiprazde combined imipramine in the treatment of treatment - refractory depression. Methods: Being used the random control study, 82 treatment - refractory depressions were divided into study group (aripiprazole and imipramimum) and control group (imipramimum and comfort). Effects and side effects were assessed with HAMD and CGI and TESS respectively before and after 4, 8weeks treatment. Results: Compared with before treatment, the total scores of HAMD and the scores of every factor were significantly decreased after 4 - week treatment with aripiprazole and imipramimum and the score of treatment factors was significantly lower than that of control group, after 4.8weeks treatment, the scores of TESS. of The control group were lower than that the study group in 4 - week. There was no significant significantly in 8weeks. Conclusions: The study suggests that aripiprazole combined with imipramimum is effective in the treatment of treatment - refractory depression.
出处 《中国民康医学》 2007年第17期721-722,共2页 Medical Journal of Chinese People’s Health
关键词 难治性抑郁症 阿立派唑 丙米嗪 Treatment - refractory depression Aripiprazole Imipramine
  • 相关文献

参考文献6

  • 1朱紫青,张明园.第3代抗精神病药阿立哌唑研究进展[J].中国医院用药评价与分析,2005,5(2):121-123. 被引量:116
  • 2中华医学会精神科分会.中国精神障碍分类与诊断标准第三版(CCMD-3)[M].济南:山东科学技术出版社,2001.118-9.
  • 3翟书涛.难治性抑郁症的治疗(上)[J].临床精神医学杂志,2001,11(5):301-303. 被引量:80
  • 4Casey DE, Carson WH, Saha AR, et al. Swithing patients to aripiprazole from other antipsychotic agents: a muhicenter randomized study [ J ]. Psychopharmacology ( Berl), 2003,166 : 391 - 399.
  • 5Gessa GL. Dysthymia and depressive disorders;dopamine hypothesis[J]. Ear Psychiatry,1996,11 (3) :1235 - 1275.
  • 6Lambert G , Johansson M, Agren H, et al . Reduced brain norepinephrine and dopamine release in treatment refractory depres sire illness;Evidence in support of cat echolamine hypothesis of mood disorders[J]. Arch Gen Psychiatry,2000,57:787 -793.

二级参考文献15

  • 1Aihara K, Shimada J, Miwa T, et al. The novel antipsychotic aripirazole is a partial agonist at short and long isoforms of D2receptors linked to the regulation of adenylyl cyclase activity and prolactin release[J] . Brain Research ,2004,1 003:9.
  • 2Bourin M, Auby P, Swanink R, et al. Aripiprazole versus haloperidol for maintained treatment effect in acute mania [M]. In: New Research Abstracts of the 156th Annual Meeting of the American Psychiatric Association; San Francisco, Calif. 2003 May 20,Abstract NR467:175.
  • 3Lieberman J, Carson WH, Saha AR, et al. Meta - analysis of the efficacy of aripirazole in schizophrenia [ J ]. Int J Neuropsychupharmacol, 2002,5 ( suppl 1 ): S186.
  • 4Marder SR, McQuade RD, Stock E, et al .Aripirazole in the treatment of schizophrenia: safety and tolerability in short term placebo - controlled trials [ J ]. Schizophr Res, 2003,61: 123.
  • 5Lieberman J. Aripirazole, The American Psychiatric Publishing Textbook of Psychopharmacology [ M ]. Third Edition. American Psychiatric Publishing, Inc .2004:487 ~ 493.
  • 6McQuade RD, Jody D, Kujawa MJ, et al. Long - term weight effects of aripiprazole versus olanzapine [ M ] . In: New Research Abstracts of the 156th Annual Meeting of the American Psychiatric Association. San Francisco, Calif. 2003May 19, Abstract NR231:86.
  • 7Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia or schizoaffective disorder [ J ]. Arch Gen Psychiatry, 2003,60:681.
  • 8Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization [ J ]. Am J Psychiatry, 1991,148:1 474.
  • 9Burns KD, Molski TF, Xu C, et al. Aripirazole, a novel antipsychotic, is a high affinity partial agonist at human dopamine D2 receptors [ J ] . J Pharmacol Exp Ther, 2002,302: 381.
  • 10De Deyn P, Jeste D, Auby P, et al. Aripiprazole for Psychosis of Alzheimer' s Disease [ poster ] [ M ]. Presented at the 16th Annual Meeting of the American Association for Geriatric Psychiatry, Honolulu, Hawaii, March 1 ~ 4, 2003.

共引文献261

同被引文献8

  • 1翟金国,赵靖平,房茂胜.新型非典型抗精神病药临床应用评价[J].中国新药与临床杂志,2006,25(4):296-301. 被引量:42
  • 2陈清刚,王莹,李刚.阿立哌唑合并氟西汀治疗难治性抑郁症[J].临床精神医学杂志,2007,17(2):106-107. 被引量:22
  • 3THASE ME. What role do atypical antipsychotic drugs have in treatment-resistant depression[J]. J Clin Psychiatry, 2002, 63 (2): 95-103.
  • 4BARBEE JG, GONRAD E J, JAMHOUR NJ. Aripiprazole augmentation in irealment-resistant depression [J]. Ann CIin Psychiatry, 2004, 16(3): 189-194.
  • 5WORTHINGTON JJ, KINRYS G, WYGANT IE. et al.Aripip-razole as an augrnentor of selective serolonin rcuptake inhibitors in depression and anxiety disorder patients [J]. Int Clin Psychophannacol, 2005, 20(1 ) : 9-11.
  • 6GESSA GL. Dysthymia and depressive disorders: dopamine hypothesis[J]. Ear Psychiatry, 1996, 11 (3) : 1235-1275.
  • 7LAMBERT G, JOHANSSON M, AGREN H, et ol. Reduced brain norepinephrine and dopamine release in lrealmen/ refractory depressive illness: evidence in support of calecholamine hypothesis of mood disorders [J]. Arch Gen Psychiatry, 2000, 57(8): 787-793.
  • 8MARDER SR, McQUADE RD, STOCK E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placbo-controlled trials [J]. Schizophr Res, 2003, 61 (2-3): 123-136.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部